1. CADTH pan-Canadian Oncology Drug Review: Vectibix for mCRC https://www.cadth.ca/vectibix-mcrc-details. Published 2015. Accessed.
2. 台灣癌症臨床研究合作組織（TCOG）. 大腸癌臨床診療手冊: 國家衛生 研究院; 2010.
3. Kopetz S CG, Overman MJ, et al. . Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27(22): 7.
4. Karapetis CS K-FS, Jonker DJ, et al. . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine 2008; 359(17): 9.
5. 化學治療在大腸直腸癌治療的角色. 長庚醫訊 2013; 34(7).
6. Yagudina R, Kulikov A, Komarov I. Budget impact analysis of bevacizumab plus chemotherapy versus bevacizumab and anti-EGFR with chemotherapy for first and second line treatment of metastatic colorectal cancer in russian federation. Value in Health 2014; 17(3): A75.
7. Rautenberg T, Siebert U, Arnold D, et al. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. Journal of Medical Economics 2014;
17(2): 99-110.
8. Methodology. WCCfDS. ATC/DDD Index 2013. . WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/.
Accessed.
9. Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, Von Der Schulenburg JM.
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European Journal of Cancer 2014; 50(1): 40-49.
10. (PBAC). PBAC. Public Summary Document: PANITUMUMAB 100 mg/5 mL injection, 1 x 5 mL vial, 400 mg/20 mL injection, 1 x 20 mL vial;
Vectibix® , Amgen Australia; 2015.
11. (PBAC). PBAC. Public Summary Document: PANITUMUMAB, injection, 100 mg/5 mL and 400 mg/20 mL, Vectibix® , Amgen Australia Pty Ltd.; 2014.
12. (PBAC). PBAC. Public Summary Document: Panitumumab, concentrate solution for infusion, 100 mg in 5mL & 400 mg in 20mL, Vectibix® ; 2013 March.
13. (PBAC). PBAC. Public Summary Document: Panitumumab, 100 mg/5 ml and
400 mg/20 ml injection, Vectibix® ; 2013 November.
14. (PBAC). PBAC. Panitumumab, concentrated solution for infusion, 20 mg per mL, 5 mL, Vectibix® . 2008.
15. Douillard JY OK, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. New England Journal of Medicine 2013; 369:
12.
16. Douillard JY, S. Siena, et al. Randomised, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. Journal of Clinical Oncology 2010; 28(31): 9.
17. Schwartzberg LSaVJW. PEAK: A randomised phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS. Journal of Clinical Oncology 2014.
18. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy NICE technology appraisal guidance 242; 2012 2012/1.
19. Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) NICE technology appraisal guidance 240; 2011 2011/12.
20. Consortium SM. Panitumumab (Vectibix® ) 2012.
21. Consortium SM. Scottish Medicines Consortium. Panitumumab 20mg/ml concentrate for solution for infusion (Vectibix® ) 2008. Report No.: 486/08.
22. NCCN Guidelines-Colon cancer. 2015.
23. Van Cutsem E ea. Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2014; 25(suppl 3): 9.
24. Maughan TS AR, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:
results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377(9783):
12.
25. Van Cutsem E KC, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 9.
26. Christopher N. Grahama GH, Marwan G. Fakihc, Hediyyih N. Knoxa, Gregory A. Maglinted, Jonas Hjelmgrenb, Beth Barberd & Lee S.
Schwartzberge. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of Medical Economics 2015; 18(8): 10.
27. Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. European Journal of Cancer 2014; 50(16): 2791-2801.
28. Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.
Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Journal of Medical Economics 2013; 16(12): 1387-1398.
29. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology 2014; 15(6): 569-579.
30. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP.
Effect of bevacizumab in older patients with metastatic colorectal cancer:
pooled analysis of four randomized studies. Journal of cancer research and clinical oncology 2010; 136(5): 737-743.
31. 衛生福利部國民健康署. 中華民國 101 年癌症登記報告: 衛 生 福 利 部 國 民 健 康 署; 2015.
32. 衛生福利部. 102 年度全民保險醫療統計年報; 2014.
33. 西 藥 、 醫 療 器 材 、 含 藥 化 粧 品 許 可 證 查 詢 . 行 政 院 衛 生 署 . http://www.fda.gov.tw/MLMS/(S(dsxxi255g1grajigoqq0pz45))/H0001.aspx. . Accessed August 24,2015.
34. 藥品給付規定：第九節 抗癌瘤藥物.: 行政院衛生署中央健康保險局. . 35. Chang YS, Chang SJ, Yeh KT, Lin TH, Chang JG. RAS, BRAF, and TP53
gene mutations in Taiwanese colorectal cancer patients. Onkologie 2013;
36(12): 719-724.
附錄
附錄一、經濟評估文獻搜尋紀錄
資料庫 查詢日期 關鍵字 篇數
PubMed 2015.08.26 1 ("panitumumab"[Supplementary Concept] OR
"panitumumab"[All Fields]) OR
("panitumumab"[Supplementary Concept] OR
"panitumumab"[All Fields] OR "vectibix"[All Fields])
1,102
2 (("oxaliplatin"[Supplementary Concept] OR
"oxaliplatin"[All Fields]) OR
("oxaliplatin"[Supplementary Concept] OR
"oxaliplatin"[All Fields] OR "eloxatin"[All Fields])) AND (("fluorouracil"[MeSH Terms]
OR "fluorouracil"[All Fields]) OR ("fluorouracil"[MeSH Terms] OR
"fluorouracil"[All Fields] OR "5 fu"[All Fields])) AND (("leucovorin"[MeSH Terms]
OR "leucovorin"[All Fields] OR ("folinic"[All Fields] AND "acid"[All Fields]) OR "folinic acid"[All Fields]) OR ("leucovorin"[MeSH Terms] OR "leucovorin"[All Fields])) OR FOLFOX[All Fields]
3,105
3 ("secondary"[Subheading] OR
"secondary"[All Fields] OR "metastatic"[All Fields]) AND ("colorectal neoplasms"[MeSH Terms] OR ("colorectal"[All Fields] AND
"neoplasms"[All Fields]) OR "colorectal neoplasms"[All Fields] OR ("colorectal"[All Fields] AND "cancer"[All Fields]) OR
"colorectal cancer"[All Fields])
30,732
4 "economics"[Subheading] OR
"economics"[All Fields] OR "cost"[All Fields]
OR "costs and cost analysis"[MeSH Terms]
OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields]
634,371
5 1#AND#2AND#3AND#4 10 Embase 2015.08.26 1 'panitumumab'/exp OR panitumumab OR
'vectibix'/exp OR vectibix
5,578 2 folfox OR (oxaliplatin OR eloxatin AND
(fluorouracil OR '5 fu') AND (folinic AND acid OR leucovorin))
11,896
3 metastatic AND colorectal AND cancer 20,411 4 'cost-benefit analysis':ab,ti OR
'cost-effectiveness':ab,ti OR 'cost
effectiveness':ab,ti OR 'cost-utility':ab,ti OR 'cost-minimization':ab,ti OR 'economic evaluation':ab,ti OR 'economic evaluation'/exp
241,391
5 #1AND #2 AND #3 AND #4 39 Cochrane
Library
2015.08.26 panitumumab
Limited to ‘economic evaluation’
5 Airiti 2015.08.26 panitumumab and metastatic colorectal cancer 8